---
title: "Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289513555.md"
description: "Humacyte entered an underwriting agreement to sell 47.6 million shares at $1.05 each, raising approximately $46.8 million in net proceeds. Underwriters have a 30-day option to purchase up to 7.1 million additional shares. The offering is expected to close around June 12, 2026."
datetime: "2026-06-11T20:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289513555.md)
  - [en](https://longbridge.com/en/news/289513555.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289513555.md)
---

# Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M

Humacyte entered into an Underwriting Agreement to sell 47,619,048 shares of common stock at $1.05 per share. Barclays Capital, BTIG, and Titan Partners Group, as representatives of the underwriters, also received a 30-day option to purchase up to 7,142,857 additional shares at the same price. Net proceeds are expected to be approximately $46.8 million, or about $53.85 million if the option is fully exercised. The offering is expected to close on or about June 12, 2026, subject to customary conditions.

**Agreement details:**

-   **Agreement type**: Underwriting agreement for common stock offering
-   **Counterparty**: Barclays Capital; BTIG; Titan Partners Group, as representatives of the underwriters
-   **Signed / Effective**: Jun 10 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Raise capital through public equity offering

Original SEC Filing: Humacyte, Inc. \[ HUMA \] - 8-K - Jun. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Humacyte ATEV meets Phase 3 V012 primary endpoint; plans supplemental BLA filing H2 2026](https://longbridge.com/en/news/289374961.md)
- [Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial](https://longbridge.com/en/news/289379825.md)
- [A Short Squeeze Is Underway in Cracker Barrel Stock. What to Know.](https://longbridge.com/en/news/289376474.md)
- [The Case for $3 Corn Revisited](https://longbridge.com/en/news/289579863.md)
- [New AI-powered puppy KPIs: Key Potty Indicators](https://longbridge.com/en/news/289668031.md)